The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Parkinson’s Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.
Some of the key takeaways from the Parkinson’s Disease Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years.
-
Parkinson’s Disease companies working in the treatment market are – FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, Chase Therapeutics Corporation, MDD US Operations, Cerevance Beta, Inc., Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, AbbVie, BrainX Corporation, AbbVie, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, CuraSen Therapeutics, Inc., Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Georgetown University, SNLD, Ltd., Il-Yang Pharm. Co., Ltd., Bial – Portela C S.A, Neuraly, Inc., Gateway Institute for Brain Research, Asklepios Biopharmaceutical, Inc., Allogeneic, Hope Pharma, Biosciences Stem Cell Research Foundation, Glaceum, Forest Hills Lab, Johns Hopkins University, Integrative Research Laboratories AB, Intra-Cellular Therapies, Inc, Jazz Pharmaceuticals, AC Immune, MeiraGTx, LLC, and others, are developing therapies for the Parkinson’s Disease treatment
-
Emerging Parkinson’s Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, CTC-413, apomorphine infusion, CVN424 150 mg, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, ABBV-951, Ceftriaxone, ABBV-951, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, CST-103, CST-107, Tavapadon, IkT-148009, Istradefylline Pill, TR-012001, Radotinib HCl 50 mg, Opicapone, NLY01, INS-GSH, AAV2-GDNF Gene therapy, Biological/Vaccine, Vutiglabridin, Gemfibrozil, AGB101, Pirepemat, Lenrispodun, Suvecaltamide, ACI-7104.056, AAAV-GAD, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.
-
In December 2023, Gain Therapeutics, a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis.
-
In December 2023, Vanqua Bio disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug VQ-101 as a potential treatment for Parkinson’s disease linked to GBA1 mutations.
-
In March 2022, Neuron23 secured a funding of $100 million to progress in Parkinson’s disease therapy. Their plan involves initiating trials for NEU-723, a potential treatment for Parkinson’s disease, by the year’s end.
-
In January 2022, The clinical-stage biotechnology company ABL Bio Inc. has partnered with Sanofi through a global licensing agreement to jointly develop and market a therapy for Parkinson’s disease and other potential medical uses. The treatment, ABL301, is a bispecific antibody in the preclinical stage designed to target alpha-synuclein and the insulin-like growth factor 1 receptor (IGF1R) while enhancing its ability to penetrate the blood-brain barrier.
Parkinson’s Disease Overview
Parkinson’s disease is a neurodegenerative disorder that primarily affects movement. It occurs when nerve cells in the brain that produce dopamine, a chemical messenger responsible for coordinating movement, become impaired or die. This results in symptoms such as tremors, stiffness, slowness of movement, and impaired balance and coordination. Parkinson’s disease is progressive, meaning symptoms worsen over time.
Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights
Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:
-
KM-819: FAScinate Therapeutics
-
Prasinezumab: Hoffmann-La Roche
-
P2B001: Pharma Two B Ltd.
-
NPT1220-478: Neuropore Therapies, Inc.
-
Dapansutrile: Olatec Therapeutics
-
UCB7853: UCB Biopharma
-
UB-312: Vaxxinity
-
Emrusolmin: Modag
-
PT320: Peptron
-
KDT-3594: Kissei Pharmaceuticals
-
CTC-413: Chase Therapeutics Corporation
-
apomorphine infusion: MDD US Operations
-
CVN424 150 mg: Cerevance Beta, Inc.
-
MT101-5: Mthera Pharma Co., Ltd.
-
BIA 28-6156: Bial R&D Investments, S.A.
-
RO7046015: Hoffmann-La Roche
-
ND0612: NeuroDerm Ltd.
-
pimavanserin tartrate: Tasly Pharmaceutical
-
ABBV-951: AbbVie
-
Ceftriaxone: BrainX Corporation
-
ABBV-951: AbbVie
-
UCB0599: UCB Biopharma SRL
-
Tocovid Suprabio (HOV-12020): National Neuroscience Institute
-
Altropane (123I) Injection: GE Healthcare
-
CST-103, CST-107: CuraSen Therapeutics, Inc.
-
Tavapadon: Cerevel Therapeutics, LLC
-
IkT-148009: Inhibikase Therapeutics, Inc.
-
Istradefylline Pill: Georgetown University
-
TR-012001: SNLD, Ltd.
-
Radotinib HCl 50 mg: Il-Yang Pharm. Co., Ltd.
-
Opicapone: Bial – Portela C S.A
-
NLY01: Neuraly, Inc.
-
INS-GSH: Gateway Institute for Brain Research
-
AAV2-GDNF Gene therapy: Asklepios Biopharmaceutical, Inc.
-
Biological/Vaccine: Allogeneic HB-adMSCs: Hope Biosciences Stem Cell Research FoundationVutiglabridin: Glaceum
-
Gemfibrozil: Forest Hills Lab
-
AGB101: Johns Hopkins University
-
Pirepemat: Integrative Research Laboratories AB
-
Lenrispodun: Intra-Cellular Therapies, Inc..
-
Suvecaltamide: Jazz Pharmaceuticals
-
ACI-7104.056: AC Immune S
-
AAAV-GAD: MeiraGTx, LLC
Parkinson’s Disease Route of Administration
Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Inhalation
-
Inhalation/Intravenous/Oral
-
Intranasal
-
Intravenous
-
Intravenous/ Subcutaneous
-
NA
-
Oral
-
Oral/intranasal/subcutaneous
-
Parenteral
-
Subcutaneous
Parkinson’s Disease Molecule Type
Parkinson’s Disease Products have been categorized under various Molecule types, such as
-
Antibody
-
Antisense oligonucleotides
-
Immunotherapy
-
Monoclonal antibody
-
Peptides
-
Protein
-
Recombinant protein
-
Small molecule
-
Stem Cell
-
Vaccine
Parkinson’s Disease Pipeline Therapeutics Assessment
-
Parkinson’s Disease Assessment by Product Type
-
Parkinson’s Disease By Stage and Product Type
-
Parkinson’s Disease Assessment by Route of Administration
-
Parkinson’s Disease By Stage and Route of Administration
-
Parkinson’s Disease Assessment by Molecule Type
-
Parkinson’s Disease by Stage and Molecule Type
DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies
Some of the key companies in the Parkinson’s Disease Therapeutics Market include:
Key companies developing therapies for Parkinson’s Disease are – Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.
Parkinson’s Disease Pipeline Analysis:
The Parkinson’s Disease pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
-
Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies
Parkinson’s Disease Pipeline Market Drivers
-
Increasing prevalence of Parkinson’s Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson’s Disease Market.
Parkinson’s Disease Pipeline Market Barriers
-
However, lack of awareness and delayed diagnosis, side effects associated with Parkinson’s disease treatment drugs and other factors are creating obstacles in the Parkinson’s Disease Market growth.
Scope of Parkinson’s Disease Pipeline Drug Insight
-
Coverage: Global
-
Key Parkinson’s Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, Chase Therapeutics Corporation, MDD US Operations, Cerevance Beta, Inc., Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, AbbVie, BrainX Corporation, AbbVie, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, CuraSen Therapeutics, Inc., Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Georgetown University, SNLD, Ltd., Il-Yang Pharm. Co., Ltd., Bial – Portela C S.A, Neuraly, Inc., Gateway Institute for Brain Research, Asklepios Biopharmaceutical, Inc., Allogeneic, Hope Pharma, Biosciences Stem Cell Research Foundation, Glaceum, Forest Hills Lab, Johns Hopkins University, Integrative Research Laboratories AB, Intra-Cellular Therapies, Inc, Jazz Pharmaceuticals, AC Immune, MeiraGTx, LLC, and others
-
Key Parkinson’s Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, CTC-413, apomorphine infusion, CVN424 150 mg, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, ABBV-951, Ceftriaxone, ABBV-951, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, CST-103, CST-107, Tavapadon, IkT-148009, Istradefylline Pill, TR-012001, Radotinib HCl 50 mg, Opicapone, NLY01, INS-GSH, AAV2-GDNF Gene therapy, Biological/Vaccine, Vutiglabridin, Gemfibrozil, AGB101, Pirepemat, Lenrispodun, Suvecaltamide, ACI-7104.056, AAAV-GAD, and others
-
Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies
-
Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers
Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials
Table of Contents
1. Parkinson’s Disease Report Introduction
2. Parkinson’s Disease Executive Summary
3. Parkinson’s Disease Overview
4. Parkinson’s Disease- Analytical Perspective In-depth Commercial Assessment
5. Parkinson’s Disease Pipeline Therapeutics
6. Parkinson’s Disease Late Stage Products (Phase II/III)
7. Parkinson’s Disease Mid Stage Products (Phase II)
8. Parkinson’s Disease Early Stage Products (Phase I)
9. Parkinson’s Disease Preclinical Stage Products
10. Parkinson’s Disease Therapeutics Assessment
11. Parkinson’s Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Parkinson’s Disease Key Companies
14. Parkinson’s Disease Key Products
15. Parkinson’s Disease Unmet Needs
16 . Parkinson’s Disease Market Drivers and Barriers
17. Parkinson’s Disease Future Perspectives and Conclusion
18. Parkinson’s Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/